← Back to search
1d3i

CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY

Method: ELECTRON MICROSCOPY Dmax: 114.1 Å Quality: GOOD
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

PROTEIN (INTERCELLULAR ADHESION MOLECULE-1)

OrganismNot specified

UniProt P05362

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 300 PDB declaration: 300-MERIC（300） Consistent with protein copy count Chain I； UniProt 28–212 Fragment：FIRST TWO DOMAINS, RESIDUES 1-185 PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP1) × 60 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP2) × 60 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP3) × 60 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP4) × 60 （P03303） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
2 Protein heterocomplex Heteromer Protein × 5 PDB declaration: pentameric（5） Consistent with protein copy count Chain I； UniProt 28–212 Fragment：FIRST TWO DOMAINS, RESIDUES 1-185 PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP1) × 1 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP2) × 1 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP3) × 1 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP4) × 1 （P03303） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
3 Protein heterocomplex Heteromer Protein × 25 PDB declaration: 25-meric（25） Consistent with protein copy count Chain I； UniProt 28–212 Fragment：FIRST TWO DOMAINS, RESIDUES 1-185 PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP1) × 5 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP2) × 5 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP3) × 5 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP4) × 5 （P03303） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
4 Protein heterocomplex Heteromer Protein × 30 PDB declaration: 30-meric（30） Consistent with protein copy count Chain I； UniProt 28–212 Fragment：FIRST TWO DOMAINS, RESIDUES 1-185 PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP1) × 6 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP2) × 6 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP3) × 6 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP4) × 6 （P03303） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
5 Protein heterocomplex Heteromer Protein × 5 PDB declaration: pentameric（5） Consistent with protein copy count Chain I； UniProt 28–212 Fragment：FIRST TWO DOMAINS, RESIDUES 1-185 PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP1) × 1 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP2) × 1 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP3) × 1 （P03303） PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP4) × 1 （P03303） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 1D3I Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 300 PDB declaration: 300-MERIC
Chain 1 28–212（185 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Heteromer；Protein × 5 PDB declaration: pentameric
Chain 1 28–212（185 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 3 Insufficient information Heteromer；Protein × 25 PDB declaration: 25-meric
Chain 1 28–212（185 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 4 Insufficient information Heteromer；Protein × 30 PDB declaration: 30-meric
Chain 1 28–212（185 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3E CRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 16 (HRV16) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY Deposited 1999-09-29 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 5 Insufficient information Heteromer；Protein × 5 PDB declaration: pentameric
Chain 1 28–212（185 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions HRV16 WAS INCUBATED WITH D1D2-ICAM-1 FOR 16 HOURS AT 34 DEGREES CELSIUS (307 KELVIN) USING A SIXTEEN-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER
Resolution 28.00 Å
1D3L D1D2-ICAM-1 FULLY GLYCOSYLATED, VARIATION OF D1-D2 INTERDOMAIN ANGLE IN DIFFERENT CRYSTAL STRUCTURES. Deposited 1999-09-29 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 28–212（185 aa） Fragment：FIRST TWO DOMAINS, RESIDUES 1-185
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions PROTEIN WAS DESIALATED WITH NEURAMINIDASE (8 HR AT 37 DEGREES IN 100 MM SODIUM ACETATE, PH 6.5, 10 MG/ML PROTEIN, 0.1 ENZYME UNIT/ML), DIALYZED AGAINST 10 MM TRIS, 25 MM NACL (PH 6.0), AND PASSED THROUGH MONO-Q COLUMN. DESIALATED MATERIAL WAS CRYSTALLIZED BY HANGING DROP METHODS: 17 MG/ML PROTEIN IN BUFFER: 10 MM TRIS,25 MM NACL,1 MM MGCL2,1 MM CACL2, WAS PRECIPITATED FROM 24-27% PEG 3350 IN SAME BUFFER.
Resolution 3.25 Å
1IAM STRUCTURE OF THE TWO AMINO-TERMINAL DOMAINS OF HUMAN INTERCELLULAR ADHESION MOLECULE-1, ICAM-1 Deposited 1998-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 28–212（185 aa） Fragment：TWO N-TERMINAL, IMMUNOGLOBULIN DOMAINS
Mutation：N103Q, N118Q, N156Q NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；PROTEIN IN 10 MM TRIS, PH 7.5, 25 MM NACL, WAS CRYSTALLIZED FROM 20% PEG 4000 IN 10 MM TRIS AS PRECIPITANT
Resolution 2.10 Å R-free 0.303
1IC1 THE CRYSTAL STRUCTURE FOR THE N-TERMINAL TWO DOMAINS OF ICAM-1 Deposited 1998-03-09 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 28–217（190 aa） Fragment：N-TERMINAL 190 RESIDUE DOMAIN
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；17% PEG 4000, NA CACODYLATE, PH 6.5, AND 100 MM B-OCTYL-GLUCOPYRANOSIDE.
Resolution 3.00 Å R-free 0.279
1IC1 THE CRYSTAL STRUCTURE FOR THE N-TERMINAL TWO DOMAINS OF ICAM-1 Deposited 1998-03-09 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric
Chain B 28–217（190 aa） Fragment：N-TERMINAL 190 RESIDUE DOMAIN
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；17% PEG 4000, NA CACODYLATE, PH 6.5, AND 100 MM B-OCTYL-GLUCOPYRANOSIDE.
Resolution 3.00 Å R-free 0.279
1MQ8 Crystal structure of alphaL I domain in complex with ICAM-1 Deposited 2002-09-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 28–318（291 aa） Fragment：domains 1 and 2
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25% PEG 4000, 0.1 M sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP at 298K
Resolution 3.30 Å R-free 0.313
1MQ8 Crystal structure of alphaL I domain in complex with ICAM-1 Deposited 2002-09-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 28–318（291 aa） Fragment：domains 1 and 2
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25% PEG 4000, 0.1 M sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP at 298K
Resolution 3.30 Å R-free 0.313
1P53 The Crystal Structure of ICAM-1 D3-D5 fragment Deposited 2003-04-24 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 212–477（266 aa） Fragment：ICAM-1 extracellular Domain 3-5, ecto-fragment
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；15mg/ml protein, NH4H2PO4, 0.1 M Na-citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.06 Å R-free 0.252
1P53 The Crystal Structure of ICAM-1 D3-D5 fragment Deposited 2003-04-24 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 212–477（266 aa） Fragment：ICAM-1 extracellular Domain 3-5, ecto-fragment
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；15mg/ml protein, NH4H2PO4, 0.1 M Na-citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.06 Å R-free 0.252
1Z7Z Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi Deposited 2005-03-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-MERIC
Chain I 28–477（450 aa） Fragment：ICAM-1 EXTRACELLULAR DOMAIN 1-5
Mutation：K29M NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 480 ELECTRON MICROSCOPY
cryo-EM buffer TRIS；pH 7.2；TRIS
cryo-EM vitrification conditions Cryogen ETHANE；PLUNGED INTO ETHANE AT LIQUID NITROGEN TEMPERATURE
Resolution 8.00 Å
1Z7Z Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi Deposited 2005-03-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain I 28–477（450 aa） Fragment：ICAM-1 EXTRACELLULAR DOMAIN 1-5
Mutation：K29M NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 ELECTRON MICROSCOPY
cryo-EM buffer TRIS；pH 7.2；TRIS
cryo-EM vitrification conditions Cryogen ETHANE；PLUNGED INTO ETHANE AT LIQUID NITROGEN TEMPERATURE
Resolution 8.00 Å
1Z7Z Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi Deposited 2005-03-28 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric
Chain I 28–477（450 aa） Fragment：ICAM-1 EXTRACELLULAR DOMAIN 1-5
Mutation：K29M NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 40 ELECTRON MICROSCOPY
cryo-EM buffer TRIS；pH 7.2；TRIS
cryo-EM vitrification conditions Cryogen ETHANE；PLUNGED INTO ETHANE AT LIQUID NITROGEN TEMPERATURE
Resolution 8.00 Å
1Z7Z Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi Deposited 2005-03-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric
Chain I 28–477（450 aa） Fragment：ICAM-1 EXTRACELLULAR DOMAIN 1-5
Mutation：K29M NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 48 ELECTRON MICROSCOPY
cryo-EM buffer TRIS；pH 7.2；TRIS
cryo-EM vitrification conditions Cryogen ETHANE；PLUNGED INTO ETHANE AT LIQUID NITROGEN TEMPERATURE
Resolution 8.00 Å
1Z7Z Cryo-em structure of human coxsackievirus A21 complexed with five domain icam-1kilifi Deposited 2005-03-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain I 28–477（450 aa） Fragment：ICAM-1 EXTRACELLULAR DOMAIN 1-5
Mutation：K29M NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 ELECTRON MICROSCOPY
cryo-EM buffer TRIS；pH 7.2；TRIS
cryo-EM vitrification conditions Cryogen ETHANE；PLUNGED INTO ETHANE AT LIQUID NITROGEN TEMPERATURE
Resolution 8.00 Å
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 10 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain S 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 11 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain U 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 12 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain W 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 13 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain Y 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 14 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain a 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain G 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain I 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain K 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain M 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain O 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
3TCX Structure of Engineered Single Domain ICAM-1 D1 with High-Affinity aL Integrin I Domain of Native C-Terminal Helix Conformation Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain Q 29–112（84 aa） Fragment：DOMAIN 1, unp residues 29-112
Mutation：T2V, I10T, T23A, P38V, P63V, S67A, T78A MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6；277 K；pH 6.0, EVAPORATION, temperature 277K
Resolution 3.60 Å R-free 0.234
5MZA The DBLb domain of PF11_0521 PfEMP1 bound to human ICAM-1 Deposited 2017-01-31 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 28–212（185 aa）
Not recorded 3PO TRIPHOSPHATE × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 IHP INOSITOL HEXAKISPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；10% (w/v) PEG 20000, 20% (v/v) PEG 500 and 0.1M Tris-BICINE (pH 8.5)
Resolution 2.78 Å R-free 0.236
6EIT Coxsackievirus A24v in complex with the D1-D2 fragment of ICAM-1 Deposited 2017-09-19 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 240 PDB declaration: 240-meric
Chain 4 28–112（85 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5；TBS buffer (Coxsackievirus A24v) Phosphate buffer (ICAM-1 D1-D2)
cryo-EM vitrification conditions Cryogen ETHANE；On-grid binding of the receptor was performed by applying 3 microliters of ICAM-1 (9.85 mg/ml) to the pre-blotted, virus-containing grid, and leaving for 30 seconds before blotting and freezing
Resolution 3.90 Å
6S8U Structure of the PfEMP1 IT4var13 DBLbeta domain bound to ICAM-1 Deposited 2019-07-10 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 28–212（185 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；0.1M Tris pH 8, 25% PEG 350 MME
Resolution 3.67 Å R-free 0.286
7BG7 HRV14 in complex with its receptor ICAM-1 Deposited 2021-01-06 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 300 PDB declaration: 300-meric
Chain B 28–480（453 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；PBS
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.40 Å

12 other PDB entries and 36 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name ICAM1_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain I； PDBConstruct 1–185； UniProt 28–212

PROTEIN (RHINOVIRUS 14 COAT PROTEIN VP1)

OrganismNot specified

UniProt P03303

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 300 PDB declaration: 300-MERIC（300） Consistent with protein copy count Chain 1； UniProt 567–855 Chain 2； UniProt 69–330 Chain 3； UniProt 331–566 Chain 4； UniProt 1–68 Not recorded PROTEIN (INTERCELLULAR ADHESION MOLECULE-1) × 60 （P05362） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
2 Protein heterocomplex Heteromer Protein × 5 PDB declaration: pentameric（5） Consistent with protein copy count Chain 1； UniProt 567–855 Chain 2； UniProt 69–330 Chain 3； UniProt 331–566 Chain 4； UniProt 1–68 Not recorded PROTEIN (INTERCELLULAR ADHESION MOLECULE-1) × 1 （P05362） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
3 Protein heterocomplex Heteromer Protein × 25 PDB declaration: 25-meric（25） Consistent with protein copy count Chain 1； UniProt 567–855 Chain 2； UniProt 69–330 Chain 3； UniProt 331–566 Chain 4； UniProt 1–68 Not recorded PROTEIN (INTERCELLULAR ADHESION MOLECULE-1) × 5 （P05362） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
4 Protein heterocomplex Heteromer Protein × 30 PDB declaration: 30-meric（30） Consistent with protein copy count Chain 1； UniProt 567–855 Chain 2； UniProt 69–330 Chain 3； UniProt 331–566 Chain 4； UniProt 1–68 Not recorded PROTEIN (INTERCELLULAR ADHESION MOLECULE-1) × 6 （P05362） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å
5 Protein heterocomplex Heteromer Protein × 5 PDB declaration: pentameric（5） Consistent with protein copy count Chain 1； UniProt 567–855 Chain 2； UniProt 69–330 Chain 3； UniProt 331–566 Chain 4； UniProt 1–68 Not recorded PROTEIN (INTERCELLULAR ADHESION MOLECULE-1) × 1 （P05362） ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：HRV14 WAS INCUBATED WITH D1D2-ICAM-1 FOR 30 MINUTES AT 4 DEGREES CELSIUS (277 KELVIN) USING AN EIGHT-FOLD EXCESS OF D1D2-ICAM-1 FOR EACH OF THE SIXTY POSSIBLE BINDING SITES PER VIRION. AFTER INCUBATION, SAMPLES WERE PREPARED AS THIN LAYERS OF VITREOUS ICE AND MAINTAINED AT NEAR LIQUID NITROGEN TEMPERATURE IN THE ELECTRON MICROSCOPE WITH A GATAN 626 CRYOTRANSFER HOLDER. Resolution 26.00 Å

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 1D3I Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1HRI STRUCTURE DETERMINATION OF ANTIVIRAL COMPOUND SCH 38057 COMPLEXED WITH HUMAN RHINOVIRUS 14 Deposited 1992-10-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded S57 1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 60 X-RAY DIFFRACTION
X-ray crystallization conditions 3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682 (5 MICROGRAM/ML).
Resolution 3.00 Å
1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682 (5 MICROGRAM/ML).
Resolution 3.00 Å
1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 5 X-RAY DIFFRACTION
X-ray crystallization conditions 3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682 (5 MICROGRAM/ML).
Resolution 3.00 Å
1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 6 X-RAY DIFFRACTION
X-ray crystallization conditions 3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682 (5 MICROGRAM/ML).
Resolution 3.00 Å
1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682 (5 MICROGRAM/ML).
Resolution 3.00 Å
1HRV HRV14/SDZ 35-682 COMPLEX Deposited 1995-03-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded SDZ 1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE × 20 X-RAY DIFFRACTION
X-ray crystallization conditions 3-4 CRYSTALS SOAKED IN 200 MICROLITER DROPS OF SDZ 35-682 (5 MICROGRAM/ML).
Resolution 3.00 Å
1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 240 PDB declaration: 240-MERIC
Chain A 568–856（289 aa）
Chain B 70–228（159 aa）
Chain B 229–331（103 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded SPH SPHINGOSINE × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å
1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa）
Chain B 70–228（159 aa）
Chain B 229–331（103 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded SPH SPHINGOSINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å
1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Insufficient information Heteromer；Protein × 20 PDB declaration: eicosameric
Chain A 568–856（289 aa）
Chain B 70–228（159 aa）
Chain B 229–331（103 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded SPH SPHINGOSINE × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å
1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Insufficient information Heteromer；Protein × 24 PDB declaration: 24-meric
Chain A 568–856（289 aa）
Chain B 70–228（159 aa）
Chain B 229–331（103 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded SPH SPHINGOSINE × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å
1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa）
Chain B 70–228（159 aa）
Chain B 229–331（103 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded SPH SPHINGOSINE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å
1K5M Crystal Structure of a Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 V3 Loop Chimeric Virus MN-III-2 Deposited 2001-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Insufficient information Heteromer；Protein × 60 PDB declaration: 60-meric
Chain A 568–856（289 aa）
Chain B 70–228（159 aa）
Chain B 229–331（103 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded SPH SPHINGOSINE × 15 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.5 M ammonium formate and 0.15 M sodium HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.70 Å
1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.30 Å R-free 0.228
1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.30 Å R-free 0.228
1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.30 Å R-free 0.228
1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.30 Å R-free 0.228
1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.30 Å R-free 0.228
1NA1 The structure of HRV14 when complexed with Pleconaril Deposited 2002-11-26 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 20 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HEPES, NaCl, CaCl2, PEG8K, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.30 Å R-free 0.228
1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 60 X-RAY DIFFRACTION
X-ray crystallization conditions The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
Resolution 2.50 Å R-free 0.217
1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
Resolution 2.50 Å R-free 0.217
1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 5 X-RAY DIFFRACTION
X-ray crystallization conditions The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
Resolution 2.50 Å R-free 0.217
1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 6 X-RAY DIFFRACTION
X-ray crystallization conditions The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
Resolution 2.50 Å R-free 0.217
1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
Resolution 2.50 Å R-free 0.217
1NCQ The structure of HRV14 when complexed with pleconaril, an antiviral compound Deposited 2002-12-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain A 568–856（289 aa）
Chain B 70–331（262 aa）
Chain C 332–567（236 aa）
Chain D 2–69（68 aa）
Not recorded W11 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE × 20 X-RAY DIFFRACTION
X-ray crystallization conditions The crystal was soaked in stabilization buffer containing 2ug/ml pleconaril before data collection
Resolution 2.50 Å R-free 0.217
1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1R08 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W42 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-(HYDROXYETHYL OXYMETHYLENEOXYMETHYL) ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 60 DMS DIMETHYL SULFOXIDE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 5 DMS DIMETHYL SULFOXIDE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 6 DMS DIMETHYL SULFOXIDE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1R09 HUMAN RHINOVIRUS 14 COMPLEXED WITH ANTIVIRAL COMPOUND R 61837 Deposited 1990-05-04 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded JEN 3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE × 20 DMS DIMETHYL SULFOXIDE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1RUC RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUD RHINOVIRUS 14 MUTANT N1105S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S Mutation：N(1)105S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUE RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 568–856（289 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 568–856（289 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 568–856（289 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 568–856（289 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 568–856（289 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUF RHINOVIRUS 14 (HRV14) (MUTANT WITH ASN 1 219 REPLACED BY ALA (N219A IN CHAIN 1) Deposited 1995-06-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 568–856（289 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A Mutation：N(1)219A No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.90 Å
1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUG RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUH RHINOVIRUS 14 MUTANT N1219S COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S Mutation：N(1)219S W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUI RHINOVIRUS 14 MUTANT S1223G COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52084 Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RUJ RHINOVIRUS 14 MUTANT WITH SER 1 223 REPLACED BY GLY (S1223G) Deposited 1995-06-09 Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G Mutation：S(1)223G No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 4.00 Å
1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 4.00 Å
1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 4.00 Å
1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 4.00 Å
1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 4.00 Å
1RVF FAB COMPLEXED WITH INTACT HUMAN RHINOVIRUS Deposited 1996-09-05 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein heterocomplex Heteromer；Protein × 120 PDB declaration: 120-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 4.00 Å
1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: complete icosahedral assembly
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 60 X-RAY DIFFRACTION
X-ray crystallization conditions 5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
Resolution 3.00 Å
1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
Resolution 3.00 Å
1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 5 X-RAY DIFFRACTION
X-ray crystallization conditions 5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
Resolution 3.00 Å
1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 6 X-RAY DIFFRACTION
X-ray crystallization conditions 5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
Resolution 3.00 Å
1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
Resolution 3.00 Å
1VRH HRV14/SDZ 880-061 COMPLEX Deposited 1996-02-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L Mutation：I(2 170)L SD8 2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER × 20 X-RAY DIFFRACTION
X-ray crystallization conditions 5 MG/ML OF SDZ 880-061 IN 200 MICROLITER DROPS FOR 3 - 4 CRYSTALS
Resolution 3.00 Å
1XR5 Crystal Structure of the RNA-dependent RNA Polymerase 3D from human rhinovirus serotype 14 Deposited 2004-10-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1720–2179（460 aa） Fragment：RNA-DIRECTED RNA POLYMERASE
Not recorded SM SAMARIUM (III) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；286 K；sodium formate, glycerol, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 286K
Resolution 2.80 Å R-free 0.293
2B0F NMR Structure of the Human Rhinovirus 3C Protease (serotype 14) with covalently bound Ace-LEALFQ-ethylpropionate inhibitor Deposited 2005-09-13 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 1538–1719（182 aa） Fragment：Human Rhinovirus serotype 14 3C Protease
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；25 K；Ionic strength (raw mmCIF value) 20mM KH2PO4；Pressure ambient
NMR measurement conditions pH 6.5；25 K；Ionic strength (raw mmCIF value) 20mM KH2PO4；Pressure ambient
NMR sample composition 0.75mM HRV14-3C with covalent inhibitor 20mM KH2PO4 15mM DTT 0.5mM EDTA 0.1mM DSS pH 6.5; 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition 0.75mM HRV14-3C with covalent inhibitor 20mM KH2PO4 15mM DTT 0.5mM EDTA 0.1mM DSS pD 6.5; 99.96% D2O | 99.96% D2O
Resolution not provided
2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWB A comparison of the anti-rhinoviral drug binding pocket in hrv14 and hrv1a Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W91 5-(3-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PROPYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2HWC A COMPARISON OF THE ANTI-RHINOVIRAL DRUG BINDING POCKET IN HRV14 AND HRV1A Deposited 1994-01-25 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W54 5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2IN2 NMR Structure of the Apo Human Rhinovirus 3C Protease (serotype 14) Deposited 2006-10-05 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1537–1718（182 aa） Fragment：Human Rhinovirus 3C Protease
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Ionic strength (raw mmCIF value) 20 mM；Pressure 1
NMR sample composition U-13C/15N; 20mM phosphate buffer; 0.5mM EDTA; 15mM DTT; 0.3% NaN3; 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition U-13C/15N; 20mM phosphate buffer; 0.5mM EDTA; 15mM DTT; NaN3; 99.6% D2O | 99.6% D2O
NMR sample composition U-15N; 20mM phosphate buffer; 0.5mM EDTA; 15mM DTT; 90% H2O, 10% D2O | 90% H2O/10% D2O
Resolution not provided
2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R04 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W71 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R06 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W35 5-(5-(4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2R07 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W33 5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RM2 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W43 5-(7-(6-CHLORO-4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RMU THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Deposited 1988-10-03 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RR1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W8R 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS1 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W84 5-(7-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS3 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W59 5-(7-(5-HYDRO-4-ETHYL-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 60 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 5 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
2RS5 STRUCTURAL ANALYSIS OF ANTIVIRAL AGENTS THAT INTERACT WITH THE CAPSID OF HUMAN RHINOVIRUSES Deposited 1988-10-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded W56 5-(5-(4-(5-HYDRO-4-METHYL-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE × 20 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 240 PDB declaration: 240-meric
Chain A 568–856（289 aa） Fragment：resdiues 568-856
Chain B 70–331（262 aa） Fragment：resdiues 70-331
Chain C 332–567（236 aa） Fragment：resdiues 332-657
Not recorded GOL GLYCEROL × 240 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 60 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
Resolution 3.00 Å R-free 0.200
4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa） Fragment：resdiues 568-856
Chain B 70–331（262 aa） Fragment：resdiues 70-331
Chain C 332–567（236 aa） Fragment：resdiues 332-657
Not recorded GOL GLYCEROL × 4 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
Resolution 3.00 Å R-free 0.200
4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 20 PDB declaration: eicosameric
Chain A 568–856（289 aa） Fragment：resdiues 568-856
Chain B 70–331（262 aa） Fragment：resdiues 70-331
Chain C 332–567（236 aa） Fragment：resdiues 332-657
Not recorded GOL GLYCEROL × 20 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
Resolution 3.00 Å R-free 0.200
4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 24 PDB declaration: 24-meric
Chain A 568–856（289 aa） Fragment：resdiues 568-856
Chain B 70–331（262 aa） Fragment：resdiues 70-331
Chain C 332–567（236 aa） Fragment：resdiues 332-657
Not recorded GOL GLYCEROL × 24 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
Resolution 3.00 Å R-free 0.200
4PDW A benzonitrile analogue inhibits rhinovirus replication Deposited 2014-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 568–856（289 aa） Fragment：resdiues 568-856
Chain B 70–331（262 aa） Fragment：resdiues 70-331
Chain C 332–567（236 aa） Fragment：resdiues 332-657
Not recorded GOL GLYCEROL × 4 2XK 4-[(4,5-dimethoxy-2-nitrophenyl)acetyl]benzonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.2；293.15 K；PEG 8000, calcium chloride
Resolution 3.00 Å R-free 0.200
4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 240 PDB declaration: 240-MERIC
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 20 PDB declaration: eicosameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 24 PDB declaration: 24-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
4RHV THE USE OF MOLECULAR-REPLACEMENT PHASES FOR THE REFINEMENT OF THE HUMAN RHINOVIRUS 14 STRUCTURE Deposited 1988-01-25 Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 80 PDB declaration: 80-meric
Chain 1 567–855（289 aa）
Chain 2 69–330（262 aa）
Chain 3 331–566（236 aa）
Chain 4 1–68（68 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.00 Å
5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 Different construct Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
5W3E CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-07 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.71 Å
5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.71 Å
5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 Different construct Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.71 Å
5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.71 Å
5W3L CryoEM structure of rhinovirus B14 in complex with C5 Fab (4 degrees Celsius, molar ratio 1:3, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.71 Å
5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 360 PDB declaration: 360-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.26 Å
5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.26 Å
5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 Different construct Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.26 Å
5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 36 PDB declaration: 36-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.26 Å
5W3M CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:1, full particle) Deposited 2017-06-08 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Chain D 2–69（68 aa） Fragment：UNP residues 2-69
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.26 Å
5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 300 PDB declaration: 300-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 25 PDB declaration: 25-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 30 PDB declaration: 30-meric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
5W3O CryoEM structure of rhinovirus B14 in complex with C5 Fab (33 degrees Celsius, molar ratio 1:3, empty particle) Deposited 2017-06-08 Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain A 568–856（289 aa） Fragment：UNP residues 568-856
Chain B 332–567（236 aa） Fragment：UNP residues 332-567
Chain C 70–331（262 aa） Fragment：UNP residues 70-331
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20 mM Tris, 120 mM sodium chloride, 1 mM EDTA, pH 8.0
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.01 Å
6HLT Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of rhinovirus-14 (HRV14) Deposited 2018-09-11 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain B 1430–1485（56 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；10% w/v PEG 8000, 20% v/v ethylene glycol, 30 mM MgCl2, 30 mM CaCl2, 100 mM bicine/Tris pH 8.5
Resolution 2.81 Å R-free 0.239
6HLT Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of rhinovirus-14 (HRV14) Deposited 2018-09-11 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 1430–1485（56 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；10% w/v PEG 8000, 20% v/v ethylene glycol, 30 mM MgCl2, 30 mM CaCl2, 100 mM bicine/Tris pH 8.5
Resolution 2.81 Å R-free 0.239
6KYZ HRV14 3C in complex with single chain antibody YDF Deposited 2019-09-20 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 1538–1719（182 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M citrate 40% PEG600
Resolution 1.84 Å R-free 0.208
6KYZ HRV14 3C in complex with single chain antibody YDF Deposited 2019-09-20 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain D 1538–1719（182 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M citrate 40% PEG600
Resolution 1.84 Å R-free 0.208
6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 1538–1719（182 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl, 25% MPEG5000, 0.2 M Li2SO4
Resolution 2.40 Å R-free 0.223
6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain D 1538–1719（182 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl, 25% MPEG5000, 0.2 M Li2SO4
Resolution 2.40 Å R-free 0.223
6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain G 1538–1719（182 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl, 25% MPEG5000, 0.2 M Li2SO4
Resolution 2.40 Å R-free 0.223
6KZ0 HRV14 3C in complex with single chain antibody GGVV Deposited 2019-09-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain J 1538–1719（182 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；0.1 M Tris-HCl, 25% MPEG5000, 0.2 M Li2SO4
Resolution 2.40 Å R-free 0.223
7BG6 HRV14 native particle solved by cryoEM Deposited 2021-01-06 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric
Chain 1 584–856（273 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；PBS with ph = 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.60 Å
7BG7 HRV14 in complex with its receptor ICAM-1 Deposited 2021-01-06 Different construct Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 300 PDB declaration: 300-meric
Chain 1 564–856（293 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；PBS
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.40 Å
7NUL Rhinovirus-14 ICAM-1 activated particle at pH 6.2 Deposited 2021-03-12 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: 300-meric
Chain 1 564–856（293 aa）
Chain 2 70–331（262 aa）
Chain 3 332–563（232 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 6.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.00 Å
7NUM Rhinovirus-14 ICAM-1 empty particle at pH 6.2 Deposited 2021-03-12 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: 300-meric
Chain 1 564–856（293 aa）
Chain 2 70–331（262 aa）
Chain 3 332–563（232 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 6.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.90 Å
7NUN Rhinovirus 14 ICAM-1 virion-like particle at pH 6.2 Deposited 2021-03-12 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric
Chain 1 564–856（293 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 6.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.60 Å
7NUO Rhinovirus 14 empty particle at pH 6.2 Deposited 2021-03-12 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: 300-meric
Chain 1 564–856（293 aa）
Chain 2 70–331（262 aa）
Chain 3 332–563（232 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 6.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.90 Å
7NUQ Rhinovirus 14 virion-like at pH 6.2 Deposited 2021-03-12 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric
Chain 1 564–856（293 aa）
Chain 2 70–331（262 aa）
Chain 3 332–567（236 aa）
Chain 4 2–69（68 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 6.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.80 Å
8PNB HRV empty capsid Deposited 2023-06-30 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 180 PDB declaration: trimeric
Chain 1 627–856（230 aa）
Chain 2 76–331（256 aa）
Chain 3 332–567（236 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.80 Å
8PNF HRV B14 virion proteins Deposited 2023-06-30 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Homooligomer；Protein × 240 PDB declaration: 300-meric
Chain 1 574–856（283 aa）
Chain 2 76–331（256 aa）
Chain 3 332–567（236 aa）
Chain 4 23–69（47 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.90 Å
9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1538–1719（182 aa）
Not recorded XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
Resolution 2.11 Å R-free 0.267
9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 1538–1719（182 aa）
Not recorded XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
Resolution 2.11 Å R-free 0.267
9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 1538–1719（182 aa）
Not recorded XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
Resolution 2.11 Å R-free 0.267
9LGP Crystal structure of the HRV B14 3C protease in complex with AG7404 Deposited 2025-01-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 1538–1719（182 aa）
Not recorded XNV ethyl (4R)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；289.15 K；0.1 M Tris-HCl, 0.8 M Lithium chloride, 36%(w/v) PEG 4000
Resolution 2.11 Å R-free 0.267
9U5P HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-dimer conformation Deposited 2025-03-21 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 6 PDB declaration: heptameric
Chain A 1539–1718（180 aa）
Chain O 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.96 Å
9U5Q HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1 Deposited 2025-03-21 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric
Chain A 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.35 Å
9U5R HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation 2 Deposited 2025-03-21 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric
Chain O 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.59 Å
9URM HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1 splitRNA Deposited 2025-04-30 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric
Chain A 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.24 Å
9VMD HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation2 splitRNA Deposited 2025-06-27 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric
Chain O 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions Resolution 4.38 Å
9WB3 HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1-composite-1 Deposited 2025-08-13 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric
Chain A 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.17 Å
9WB4 HRV14 3C in complex with single chain antibody YDF and cloverleafRNA-conformation1-composite-2 Deposited 2025-08-13 Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein–RNA Heteromer；Protein × 3 PDB declaration: tetrameric
Chain A 1539–1718（180 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.32 Å

58 other PDB entries and 236 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name POLG_HRV14
Isoform —
PDB entities 2, 3, 4, 5
Chains and sequence ranges Author chain 1； PDBConstruct 1–289； UniProt 567–855 Author chain 2； PDBConstruct 1–262； UniProt 69–330 Author chain 3； PDBConstruct 1–236； UniProt 331–566 Author chain 4； PDBConstruct 1–68； UniProt 1–68

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 1d3i

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 1d3i
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id1d3i
Deposition date deposition_date1999-09-29
Structure title titleCRYO-EM STRUCTURE OF HUMAN RHINOVIRUS 14 (HRV14) COMPLEXED WITH A TWO-DOMAIN FRAGMENT OF ITS CELLULAR RECEPTOR, INTERCELLULAR ADHESION MOLECULE-1 (D1D2-ICAM-1). IMPLICATIONS FOR VIRUS-RECEPTOR INTERACTIONS. ALPHA CARBONS ONLY
Keywords keywords;HUMAN RHINOVIRUS, HRV14, ICAM-1, FITTING OF X-RAY STRUCTURES INTO CRYO-EM RECONSTRUCTIONS, COMMON COLD, VIRUS UNCOATING, VIRUS/ VIRAL PROTEIN, RHINOVIRUS-RECEPTOR COMPLEX, Icosahedral virus, Virus-Receptor COMPLEX ;; Virus/Receptor
Experimental Method methodELECTRON MICROSCOPY
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier33.90 Å
Radius of gyration Rg (electron density) rg_electron33.49 Å
Forward intensity I(0) i0182260000.00
Molecular weight molecular_weight109410.0 kDa
Excluded volume excluded_volume133650 ų
Envelope volume envelope_volume118210 ų
Hydration-shell volume shell_volume33103 ų
Envelope diameter envelope_diameter123.2 Å
Shell Rg shell_rg35.89 Å
Envelope Rg envelope_rg31.88 Å
Shape Rg shape_rg33.47 Å
Total Rg total_rg33.64 Å
Total atoms total_atoms—
Residues n_residues—
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax114.1 Å
Rg (real space) rg_real33.94 Å
Rg uncertainty (real space) rg_real_error0.87 Å
I(0) (real space) i0_real1.8230e+08
I(0) uncertainty (real space) i0_real_error2.9940e+06
Rg (reciprocal space) rg_reciprocal33.92 Å
I(0) (reciprocal space) i0_reciprocal182300000.0000
Solution quality estimate total_estimate0.8823
Solution quality rating solution_quality GOOD a GOOD solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary36.4 Å
Skewness Skewness skewness0.378
Kurtosis Kurtosis kurtosis-0.368
Angular range angular_range— – 0.2350 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha19970000.0000
Real-space data points n_real_points48
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.858; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.949; Smooth: 0.941
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (5)

▼

7. Fold Classification (SCOP + CATH) 5 domains

SCOP 2.08 (5 domains)

Domain ID domain_idd1d3i1_
Class classi — Low resolution protein structures
Fold Fold foldi.6 — Viruses and virus-receptor complexes
Superfamily Superfamily superfamilyi.6.1 — Viruses and virus-receptor complexes
Family Family familyi.6.1.1 — Viruses and virus-receptor complexes
Domain ID domain_idd1d3i2_
Class classi — Low resolution protein structures
Fold Fold foldi.6 — Viruses and virus-receptor complexes
Superfamily Superfamily superfamilyi.6.1 — Viruses and virus-receptor complexes
Family Family familyi.6.1.1 — Viruses and virus-receptor complexes
Domain ID domain_idd1d3i3_
Class classi — Low resolution protein structures
Fold Fold foldi.6 — Viruses and virus-receptor complexes
Superfamily Superfamily superfamilyi.6.1 — Viruses and virus-receptor complexes
Family Family familyi.6.1.1 — Viruses and virus-receptor complexes
Domain ID domain_idd1d3i4_
Class classi — Low resolution protein structures
Fold Fold foldi.6 — Viruses and virus-receptor complexes
Superfamily Superfamily superfamilyi.6.1 — Viruses and virus-receptor complexes
Family Family familyi.6.1.1 — Viruses and virus-receptor complexes
Domain ID domain_idd1d3ii_
Class classi — Low resolution protein structures
Fold Fold foldi.6 — Viruses and virus-receptor complexes
Superfamily Superfamily superfamilyi.6.1 — Viruses and virus-receptor complexes
Family Family familyi.6.1.1 — Viruses and virus-receptor complexes
▶

8. Citations (6)

▶

9. Files and Curves (10)